New painkiller may offer longer relief after gallbladder surgery

NCT ID NCT07577934

Recruiting now Symptom relief Sponsor: Tianjin First Central Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a long-acting painkiller (liposomal bupivacaine) works better than a standard one (ropivacaine) for pain after gallbladder removal. About 86 adults having laparoscopic cholecystectomy will receive one of the two drugs via a nerve block during surgery. Researchers will measure pain levels, recovery quality, and side effects over three months to see which option provides better pain control and faster recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liposomal bupivacaine
What this could lead to: If liposomal bupivacaine works better, it could provide longer-lasting pain relief after gallbladder surgery, helping patients recover faster and possibly reducing the risk of long-term pain.
What could go wrong: This is a small, early-stage trial with only 86 people. The results may not apply to everyone, and there is no guarantee that liposomal bupivacaine will be more effective than the standard drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIPOSOMAL BUPIVACAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIPOSOMAL BUPIVACAINE POSTOPERATIVE PAIN

Contacts and locations

Locations

Tianjin First Central Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300384, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.